{"answer":{"query":"ibrance","resolved_as":"name","packages":9,"applications":["NDA207103","NDA212436"],"identity":{"application_numbers":["NDA207103","NDA212436"],"marketing_categories":["NDA"],"labelers":[{"text":"PFIZER LABORATORIES DIV PFIZER INC","untrusted":true}],"dosage_forms":[{"text":"CAPSULE","untrusted":true},{"text":"TABLET, FILM COATED","untrusted":true}],"marketing_start":{"earliest":"2015-02-03","latest":"2020-03-30","packages_with_a_start_date":6}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":9,"negotiated_price_ends":null,"rows":[{"ndc":"00069018721","name":{"text":"Ibrance (Palbociclib) 75mg Cap","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069018821","name":{"text":"Ibrance (Palbociclib) 100mg Cap","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069018921","name":{"text":"Ibrance (Palbociclib) 125mg Cap","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069028403","name":{"text":"IBRANCE 75MG FCT 3X7 BLS US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069028407","name":{"text":"IBRANCE 75MG FCT BLS US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069048603","name":{"text":"IBRANCE 100MG FCT 3X7 BLS US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069048607","name":{"text":"IBRANCE 100MG FCT BLS US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069068803","name":{"text":"IBRANCE 125MG FCT 3X7 BLS US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00069068807","name":{"text":"IBRANCE 125MG FCT BLS US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":7871,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA207103","date":"2034-08-08","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10723730*PED","productNo":"002"},"latest_patent_expiry":"2034-08-08","latest_exclusivity_expiry":"2029-06-24","dated_barriers":21,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":2,"exclusivities_listed":3,"fact_id":"480b6a09c99ce8a0793e9754"},{"application":"NDA212436","date":"2037-02-19","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"11065250*PED","productNo":"002"},"latest_patent_expiry":"2037-02-19","latest_exclusivity_expiry":"2029-06-24","dated_barriers":27,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":3,"exclusivities_listed":3,"fact_id":"e7e97be9353af11f2631e290"}],"label_history":{"events_total":24,"non_cmc_events":23,"counts_by_class":{"EFFICACY":15,"LABELING":8},"cmc_events":1,"recent_non_cmc_events":[{"application":"NDA207103","submission_no":24,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-06-24","documents":[{"type":"Letter","date":"2026-06-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/207103Orig1s024ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-06-29","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/207103s024lbl.pdf","untrusted":true}}],"fact_id":"a5fe55181a1b02c4b8790d6a"},{"application":"NDA212436","submission_no":12,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-06-24","documents":[{"type":"Letter","date":"2026-06-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/212436Orig1s012ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-06-29","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212436s012lbl.pdf","untrusted":true}}],"fact_id":"34bf9980807886fa047e38a7"},{"application":"NDA207103","submission_no":23,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-09-16","documents":[{"type":"Label","date":"2025-09-17","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207103s023lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-09-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/207103Orig1s023;212436Orig1s011ltr.pdf","untrusted":true}}],"fact_id":"2b863be71d139ebd4a32c9aa"},{"application":"NDA212436","submission_no":11,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-09-16","documents":[{"type":"Label","date":"2025-09-17","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212436s011lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-09-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/207103Orig1s023;212436Orig1s011ltr.pdf","untrusted":true}}],"fact_id":"92b40a07900cc13203dd2cb3"},{"application":"NDA207103","submission_no":20,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-04-23","documents":[{"type":"Label","date":"2025-04-24","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207103s020lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-05-01","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/207103Orig1s020; 212436Orig1s008ltr.pdf","untrusted":true}}],"fact_id":"c78fe42b9927dff030e34809"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":6,"te_code_counts":{"NOT_PROVIDED":3,"AB":3},"marketing_status_counts":{"Prescription":6},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA207103","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IBRANCE","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"125MG","untrusted":true}},{"application":"NDA207103","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IBRANCE","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"100MG","untrusted":true}},{"application":"NDA207103","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IBRANCE","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"75MG","untrusted":true}},{"application":"NDA212436","product_no":"003","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"IBRANCE","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"125MG","untrusted":true}},{"application":"NDA212436","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"IBRANCE","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"100MG","untrusted":true}},{"application":"NDA212436","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"IBRANCE","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"75MG","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":6,"most_recent":[{"recall_number":"D-0777-2018","classification":"Class II","status":"Terminated","report_date":"2018-05-16","recall_initiated":"2018-04-03","recalling_firm":{"text":"Kroger Specialty Pharmacy, Inc.","untrusted":true},"reason":{"text":"Lack of Processing Controls.","untrusted":true},"packages_named":1,"fact_id":"82d18260a41c1ad239b67431"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"supply":{"fda_shortage_status_counts":{"To Be Discontinued":2},"packages_with_a_termination_date":2,"next_package_termination_dates":["2029-03-31","2029-07-31"],"packages_with_future_termination_date":2,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"PALBOCICLIB","untrusted":true},"recruiting_interventional_count":61,"not_yet_recruiting_count":20,"by_phase":{"PHASE1/PHASE2":15,"PHASE2":22,"PHASE3":9,"PHASE1":8,"EARLY_PHASE1":1,"NA":6},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT03424005","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2018-03-30","link":{"text":"https://clinicaltrials.gov/study/NCT03424005","untrusted":true}},{"nct_id":"NCT06126276","title":{"text":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2024-05-07","link":{"text":"https://clinicaltrials.gov/study/NCT06126276","untrusted":true}},{"nct_id":"NCT07174336","title":{"text":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Eli Lilly and Company","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2025-12-22","link":{"text":"https://clinicaltrials.gov/study/NCT07174336","untrusted":true}},{"nct_id":"NCT04802759","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-03","start_date":"2021-06-22","link":{"text":"https://clinicaltrials.gov/study/NCT04802759","untrusted":true}},{"nct_id":"NCT05564377","title":{"text":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-02","start_date":"2023-04-07","link":{"text":"https://clinicaltrials.gov/study/NCT05564377","untrusted":true}}],"fact_id":"1b9882c31ab6e0465e988b06"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Pfizer RxPathways","untrusted":true},"type":"manufacturer","url":"https://www.pfizerrxpathways.com/","status":{"state":"limited","effective":"2025-01-01","applies_to":{"text":"Medicare Part D patients requesting help with a Pfizer product covered under their plan","untrusted":true},"detail":{"text":"Pfizer RxPathways states that from 2025-01-01 Medicare Part D patients must first enroll in the Medicare Prescription Payment Plan and submit proof of enrollment with their application, and, before being considered, must apply to all open, relevant diagnosis-specific independent charitable patient assistance programs and submit written proof of any denial. The page that states this is headed 2025 PAP changes; no later update was on the page when read.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://www.pfizerrxpathways.com/updates","proof_state":"verified"},"needs_status_check":true,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Palbociclib","untrusted":true},"brand":{"text":"Ibrance","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":2108937188.3,"claims":165133,"beneficiaries":21394,"average_spending_per_claim_usd":12771.143189,"fact_id":"3d8df8bc9ec67685bc69c44c"},{"year":2021,"gross_spending_usd":1891416132.1,"claims":140478,"beneficiaries":18781,"average_spending_per_claim_usd":13464.144792,"fact_id":"919bb3f8c03a295114a4f474"},{"year":2022,"gross_spending_usd":1948323853.7,"claims":134834,"beneficiaries":17497,"average_spending_per_claim_usd":14449.796444,"fact_id":"4d9942364e4b147f9fbf52e4"},{"year":2023,"gross_spending_usd":2020903604.2,"claims":128974,"beneficiaries":16015,"average_spending_per_claim_usd":15669.077521,"fact_id":"994554eee7d22902a2998a0e"},{"year":2024,"gross_spending_usd":2035022061.3,"claims":131537,"beneficiaries":15923,"average_spending_per_claim_usd":15471.099853,"fact_id":"46eb56579f3180f51b7f1ca2"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":7,"all_states_medicaid_reimbursed_usd":6830069.68,"all_states_medicaid_paid_prescriptions":453,"top_states":[{"state":"KY","medicaid_paid_prescriptions":87,"medicaid_reimbursed_usd":1169482.96,"total_reimbursed_usd":1169482.96,"packages":1,"covers":"fee_for_service_only","fact_id":"c4060955d7c09d8c680d707e"},{"state":"CA","medicaid_paid_prescriptions":77,"medicaid_reimbursed_usd":1140186.64,"total_reimbursed_usd":1140186.64,"packages":1,"covers":"all_record_types","fact_id":"6f0a9186a3a1d48647313fd3"},{"state":"NJ","medicaid_paid_prescriptions":68,"medicaid_reimbursed_usd":1082027.29,"total_reimbursed_usd":1082027.29,"packages":1,"covers":"all_record_types","fact_id":"8d37082d2c5a4cc69601c35e"},{"state":"WV","medicaid_paid_prescriptions":63,"medicaid_reimbursed_usd":1012284.67,"total_reimbursed_usd":1035964.99,"packages":1,"covers":"all_record_types","fact_id":"91ca8da25fdfbc4410dd8810"},{"state":"CT","medicaid_paid_prescriptions":55,"medicaid_reimbursed_usd":938370.39,"total_reimbursed_usd":938370.39,"packages":1,"covers":"all_record_types","fact_id":"2965aec22728f311761d4715"},{"state":"NC","medicaid_paid_prescriptions":51,"medicaid_reimbursed_usd":839952.24,"total_reimbursed_usd":839952.24,"packages":1,"covers":"fee_for_service_only","fact_id":"53d4ab0fd48d5049be4d9a4e"},{"state":"IL","medicaid_paid_prescriptions":52,"medicaid_reimbursed_usd":647765.49,"total_reimbursed_usd":647765.49,"packages":1,"covers":"fee_for_service_only","fact_id":"c420f4a401ac5af240d87fcd"}],"unlabelled_state_code_xx":null,"built_from_facts":7,"facts_fee_for_service_only":3,"older_year_facts_not_used":81,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"456b0d3a54fee4fb2099e8fa","field":"ndc.listing","entity":"ndc:00069018721"},{"fact_id":"d3c957a58360a3c68a313be7","field":"ndc.listing","entity":"ndc:00069018821"},{"fact_id":"b38e5b24fc35674633967245","field":"ndc.listing","entity":"ndc:00069018921"},{"fact_id":"480b6a09c99ce8a0793e9754","field":"drug.generic_entry_earliest","entity":"application:NDA207103"},{"fact_id":"7379202c1e82a65ec3f6d2a9","field":"drug.patent","entity":"application:NDA207103"},{"fact_id":"4c24e4a6a7c2adb008351ff2","field":"drug.exclusivity","entity":"application:NDA207103"},{"fact_id":"e7e97be9353af11f2631e290","field":"drug.generic_entry_earliest","entity":"application:NDA212436"},{"fact_id":"4f9cc506daf81d5eb760251a","field":"drug.patent","entity":"application:NDA212436"},{"fact_id":"7b17ae1eafd773dd1058ef77","field":"drug.exclusivity","entity":"application:NDA212436"},{"fact_id":"a5fe55181a1b02c4b8790d6a","field":"drug.label_event","entity":"application:NDA207103"},{"fact_id":"34bf9980807886fa047e38a7","field":"drug.label_event","entity":"application:NDA212436"},{"fact_id":"2b863be71d139ebd4a32c9aa","field":"drug.label_event","entity":"application:NDA207103"},{"fact_id":"92b40a07900cc13203dd2cb3","field":"drug.label_event","entity":"application:NDA212436"},{"fact_id":"c78fe42b9927dff030e34809","field":"drug.label_event","entity":"application:NDA207103"},{"fact_id":"c5e3dc7bb972d6a3d74cb1e3","field":"drug.marketing_status","entity":"application:NDA207103"},{"fact_id":"a512dfe1141afc4bc7e68316","field":"drug.marketing_status","entity":"application:NDA207103"},{"fact_id":"79ba413647eaceb5049db18a","field":"drug.marketing_status","entity":"application:NDA207103"},{"fact_id":"db85018991a95c0200e254a7","field":"drug.te_code","entity":"application:NDA212436"},{"fact_id":"e7fba4f164813b584fa1f484","field":"drug.marketing_status","entity":"application:NDA212436"},{"fact_id":"b2c2ffb55a757b334efafd18","field":"drug.te_code","entity":"application:NDA212436"},{"fact_id":"4e7190693e91f618ba7d0dca","field":"drug.marketing_status","entity":"application:NDA212436"},{"fact_id":"52b983f528435fd9fb1dadb7","field":"drug.te_code","entity":"application:NDA212436"},{"fact_id":"cb8ebe87ead67ec904d18d9f","field":"drug.marketing_status","entity":"application:NDA212436"},{"fact_id":"82d18260a41c1ad239b67431","field":"ndc.recall","entity":"ndc:00069018921"},{"fact_id":"6ed16ecf1b7ff004865c18e3","field":"ndc.shortage_row","entity":"ndc:00069018721"},{"fact_id":"330c0cdf47f444f525caf6c3","field":"ndc.shortage_row","entity":"ndc:00069018821"},{"fact_id":"fdb562d4ebec43df46570839","field":"ndc.product","entity":"ndc:00069018721"},{"fact_id":"ed5988005eb8194eb90d3986","field":"ndc.product","entity":"ndc:00069018821"},{"fact_id":"1b9882c31ab6e0465e988b06","field":"drug.trial_access","entity":"drug:palbociclib"},{"fact_id":"fceda12b103c15aaafe7bdd7","field":"program.status","entity":"program:pfizer-rxpathways"},{"fact_id":"3d8df8bc9ec67685bc69c44c","field":"drug.partd_spending","entity":"drug:palbociclib|ibrance"},{"fact_id":"919bb3f8c03a295114a4f474","field":"drug.partd_spending","entity":"drug:palbociclib|ibrance"},{"fact_id":"4d9942364e4b147f9fbf52e4","field":"drug.partd_spending","entity":"drug:palbociclib|ibrance"},{"fact_id":"994554eee7d22902a2998a0e","field":"drug.partd_spending","entity":"drug:palbociclib|ibrance"},{"fact_id":"46eb56579f3180f51b7f1ca2","field":"drug.partd_spending","entity":"drug:palbociclib|ibrance"},{"fact_id":"c4060955d7c09d8c680d707e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069068803:KY"},{"fact_id":"6f0a9186a3a1d48647313fd3","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069018721:CA"},{"fact_id":"8d37082d2c5a4cc69601c35e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069018921:NJ"},{"fact_id":"91ca8da25fdfbc4410dd8810","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069048603:WV"},{"fact_id":"2965aec22728f311761d4715","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069028403:CT"},{"fact_id":"53d4ab0fd48d5049be4d9a4e","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069018921:NC"},{"fact_id":"c420f4a401ac5af240d87fcd","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00069018921:IL"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}